SGLT2 Receptor Inhibitor Therapeutics for Patients with
Cardio-Renal-Metabolic Disorders: The Pharmacist’s Role
CPE Midday Symposium at the 2021 ASHP Midyear Clinical Meeting
**To view this CPE lecture beginning on Wednesday, December 8th at 1:00 pm ET, visit: https://us02web.zoom.us/j/82996569434
Wednesday, December 8th, 2021
1:00 pm – 2:30 pm Eastern Time
Virtual, Live Streamed Program
Recent clinical trials link cardiovascular, metabolic, and renal diseases, challenging the traditional clinician roles in healthcare. Optimal patient care now requires a shared responsibility of medication management between primary care practitioners, cardiologists, endocrinologists, and nephrologists. Pharmacists are uniquely poised to oversee and intervene on medication selection, dosing, and monitoring of patient outcomes. Our program will identify the connections of diabetes-heart failure-kidney disease while exploring the role pharmacists can play in optimizing new therapies.
I. The Interconnection of Cardio-Renal-Metabolic Disorders and the Science of SGLT2 Receptor Inhibitors – John Fanikos, RPh, MBA
II. Clinical Trial Update for SGLT2i Therapeutics Targeting Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease – Leo Buckley, PharmD
III. The Pharmacist’s Role in the Application of SGLT2 Receptor Inhibitors to Manage T2D, Reducing Hospital Admissions for HF, Reducing CVD Deaths, and Slowing the Progression of CKD, Especially in the Pandemic Era of COVID-19 – Craig Beavers, PharmD
IV. Interactive Expert Panel Discussion – John Fanikos, RPh, MBA and Expert Faculty
- Understand the interconnection of cardio-renal-metabolic disorders and the science of SGLT2 receptor inhibitors
- Analyze recent clinical trial data for SGLT2i therapeutics targeting type 2 diabetes, heart failure, and chronic kidney disease
- Review the optimal role of pharmacists in the applications of SGLT2 receptor inhibitors to manage type 2 diabetes, reduce hospital admissions for heart failure, reduce cardiovascular deaths, and slowing the progression of chronic kidney disease, especially in the pandemic era of COVID-19
John Fanikos, RPh, MBA
Assistant Professor of Clinical Pharmacy Practice
Massachusetts College of Pharmacy
Director of Pharmacy Business and Financial Services
Brigham and Women’s Hospital
Craig Beavers, PharmD
Centennial Medical Center
Leo Buckley, PharmD
Brigham and Women’s Hospital
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-024-L04-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300.
This activity is supported by an independent educational grant from Boehringer Ingelheim
Provided by AcademicCME